| Date:March _23 rd 2022 | |
|---------------------------------------|-----------------------------------------------------------------------|
| Your Name:Kai-Bo Chen | |
| Manuscript Title:_ Successful outcome | of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for |
| potentially unresectable esophagogast | ric junctional squamous cell carcinoma: a case report |
| Manuscript number (if known): | TCR-22-789 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | the Basic Public Welfare Research Project of Zhejiang Province | Kai-Bo Chen was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) |
| | medical writing, article processing charges, etc.) No time limit for this item. | Natural Science foundation of Zhejiang Province (NO. LY19H160042) | Mu-Xing Kang was funded by Natural Science foundation of Zhejiang Province (NO. LY19H160042) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |

| 3 | Royalties or licenses | _ X None |
|----|---------------------------------------------------|-----------------|
| | | |
| 4 | Consulting fees | _ X None |
| | | |
| _ | | |
| 5 | Payment or honoraria for lectures, presentations, | _ X None |
| | speakers bureaus, | |
| | manuscript writing or educational events | |
| 6 | Payment for expert | XNone |
| | testimony | |
| | | |
| 7 | Support for attending meetings and/or travel | _ X None |
| | | |
| | | |
| 8 | Patents planned, issued or | _ X None |
| | pending | |
| | | |
| 9 | Participation on a Data | _ XNone |
| | Safety Monitoring Board or Advisory Board | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | XNone |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | _ X None |
| | | |
| 12 | Descript of any in the | V |
| 12 | Receipt of equipment, materials, drugs, medical | _ X None |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | _ X None |
| | financial interests | |
| | | |

This study was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) and Natural Science foundation of Zhejiang Province (No. LY19H160042). And there is no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: March _23 rd 2022 | |
|-------------------------------------------|-----------------------------------------------------------------------|
| Your Name:Zhi-Wei Wu | |
| Manuscript Title: _ Successful outcom | of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for |
| potentially unresectable esophagogas | ric junctional squamous cell carcinoma: a case report |
| Manuscript number (if known): | TCR-22-789 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | the Basic Public Welfare Research Project of Zhejiang Province | Kai-Bo Chen was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) |
| | medical writing, article processing charges, etc.) No time limit for this item. | Natural Science foundation of Zhejiang Province (NO. LY19H160042) | Mu-Xing Kang was funded by Natural Science foundation of Zhejiang Province (NO. LY19H160042) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |

| 3 | Royalties or licenses | _ X None |
|----|----------------------------------------------------|-----------------|
| | | |
| 4 | Consulting fees | _ X None |
| | | |
| | | |
| 5 | Payment or honoraria for | _ X None |
| | lectures, presentations, speakers bureaus, | |
| | manuscript writing or educational events | |
| 6 | Payment for expert | X None |
| | testimony | |
| | | |
| 7 | Support for attending meetings and/or travel | _ X None |
| | | |
| | | |
| 8 | Patents planned, issued or | X None |
| | pending | |
| _ | | |
| 9 | Participation on a Data Safety Monitoring Board or | XNone |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | NNone |
| | committee or advocacy group, paid or unpaid | |
| 11 | Stock or stock options | _ X None |
| | | |
| | | |
| 12 | Receipt of equipment, | _ X None |
| | materials, drugs, medical | |
| | writing, gifts or other services | |
| 13 | Other financial or non- | _ X None |
| | financial interests | |
| | | |

This study was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) and Natural Science foundation of Zhejiang Province (No. LY19H160042). And there is no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date:March _23 rd 2022 | |
|----------------------------------------|-----------------------------------------------------------------------|
| Your Name:Yi Huang | |
| Manuscript Title: _ Successful outcome | of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for |
| potentially unresectable esophagogast | ic junctional squamous cell carcinoma: a case report |
| Manuscript number (if known): | TCR-22-789 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | the Basic Public Welfare Research Project of Zhejiang Province | Kai-Bo Chen was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) |
| | medical writing, article processing charges, etc.) No time limit for this item. | Natural Science foundation of Zhejiang Province (NO. LY19H160042) | Mu-Xing Kang was funded by Natural Science foundation of Zhejiang Province (NO. LY19H160042) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |

| 3 | Royalties or licenses | _ X None |
|----|----------------------------------------------------|-----------------|
| | | |
| 4 | Consulting fees | _ X None |
| | | |
| | | |
| 5 | Payment or honoraria for | _ X None |
| | lectures, presentations, speakers bureaus, | |
| | manuscript writing or educational events | |
| 6 | Payment for expert | X None |
| | testimony | |
| | | |
| 7 | Support for attending meetings and/or travel | _ X None |
| | | |
| | | |
| 8 | Patents planned, issued or | X None |
| | pending | |
| _ | | |
| 9 | Participation on a Data Safety Monitoring Board or | XNone |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | NNone |
| | committee or advocacy group, paid or unpaid | |
| 11 | Stock or stock options | _ X None |
| | | |
| | | |
| 12 | Receipt of equipment, | _ X None |
| | materials, drugs, medical | |
| | writing, gifts or other services | |
| 13 | Other financial or non- | _ X None |
| | financial interests | |
| | | |

This study was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) and Natural Science foundation of Zhejiang Province (No. LY19H160042). And there is no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date:March _23 rd 2022 |
|-------------------------------------------------------------------------------------------------------------|
| Your Name:Mu-Xing Kang |
| Manuscript Title:_ Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for |
| potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report |
| Manuscript number (if known): TCR-22-789 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | the Basic Public Welfare Research Project of Zhejiang Province | Kai-Bo Chen was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) |
| | medical writing, article processing charges, etc.) No time limit for this item. | Natural Science foundation of Zhejiang Province (NO. LY19H160042) | Mu-Xing Kang was funded by Natural Science foundation of Zhejiang Province (NO. LY19H160042) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | X None | |
| | in item #1 above). | | |

| 3 | Royalties or licenses | _ X None |
|----|---------------------------------------------------|-----------------|
| | | |
| 4 | Consulting fees | _ X None |
| | | |
| _ | | |
| 5 | Payment or honoraria for lectures, presentations, | _ X None |
| | speakers bureaus, | |
| | manuscript writing or educational events | |
| 6 | Payment for expert | XNone |
| | testimony | |
| | | |
| 7 | Support for attending meetings and/or travel | _ X None |
| | | |
| | | |
| 8 | Patents planned, issued or | _ X None |
| | pending | |
| | | |
| 9 | Participation on a Data | _ XNone |
| | Safety Monitoring Board or Advisory Board | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | XNone |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | _ X None |
| | | |
| 12 | Descript of any in the | V |
| 12 | Receipt of equipment, materials, drugs, medical | _ X None |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | _ X None |
| | financial interests | |
| | | |

This study was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) and Natural Science foundation of Zhejiang Province (No. LY19H160042). And there is no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date: March _23 rd 2022 | | |
|-------------------------------------------|----------------------|---------------------------------------------------|
| Your Name:Le-Le Lin | | |
| Manuscript Title:_ Successful outcome | of neoadjuvant PD-1 | blockade, VEGFR-2 inhibitor plus chemotherapy for |
| potentially unresectable esophagogastr | ic junctional squamo | us cell carcinoma: a case report |
| Manuscript number (if known): | TCR-22-789 | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | the Basic Public Welfare Research Project of Zhejiang Province | Kai-Bo Chen was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) |
| | medical writing, article processing charges, etc.) No time limit for this item. | Natural Science foundation of Zhejiang Province (NO. LY19H160042) | Mu-Xing Kang was funded by Natural Science foundation of Zhejiang Province (NO. LY19H160042) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |

| 3 | Royalties or licenses | _ X None |
|----|----------------------------------------------------|-----------------|
| | | |
| 4 | Consulting fees | _ X None |
| | | |
| | | |
| 5 | Payment or honoraria for | _ X None |
| | lectures, presentations, speakers bureaus, | |
| | manuscript writing or educational events | |
| 6 | Payment for expert | X None |
| | testimony | |
| | | |
| 7 | Support for attending meetings and/or travel | _ X None |
| | | |
| | | |
| 8 | Patents planned, issued or | X None |
| | pending | |
| _ | | |
| 9 | Participation on a Data Safety Monitoring Board or | XNone |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | NNone |
| | committee or advocacy group, paid or unpaid | |
| 11 | Stock or stock options | _ X None |
| | | |
| | | |
| 12 | Receipt of equipment, | _ X None |
| | materials, drugs, medical | |
| | writing, gifts or other services | |
| 13 | Other financial or non- | _ X None |
| | financial interests | |
| | | |

This study was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) and Natural Science foundation of Zhejiang Province (No. LY19H160042). And there is no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date:March _23 rd 2022 |
|-------------------------------------------------------------------------------------------------------------|
| Your Name:Shan-shan Jiang |
| Manuscript Title:_ Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for |
| potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report |
| Manuscript number (if known): TCR-22-789 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | the Basic Public Welfare Research Project of Zhejiang Province | Kai-Bo Chen was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) |
| | medical writing, article processing charges, etc.) No time limit for this item. | Natural Science foundation of Zhejiang Province (NO. LY19H160042) | Mu-Xing Kang was funded by Natural Science foundation of Zhejiang Province (NO. LY19H160042) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated | X None | |
| | in item #1 above). | | |

| 3 | Royalties or licenses | _ X None |
|----|---------------------------------------------------|-----------------|
| | | |
| 4 | Consulting fees | _ X None |
| | | |
| _ | | |
| 5 | Payment or honoraria for lectures, presentations, | _ X None |
| | speakers bureaus, | |
| | manuscript writing or educational events | |
| 6 | Payment for expert | XNone |
| | testimony | |
| | | |
| 7 | Support for attending meetings and/or travel | _ X None |
| | | |
| | | |
| 8 | Patents planned, issued or | _ X None |
| | pending | |
| | | |
| 9 | Participation on a Data | _ X None |
| | Safety Monitoring Board or Advisory Board | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | XNone |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | _ X None |
| | | |
| 12 | Descript of any in the | V |
| 12 | Receipt of equipment, materials, drugs, medical | _ X None |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | _ X None |
| | financial interests | |
| | | |

This study was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) and Natural Science foundation of Zhejiang Province (No. LY19H160042). And there is no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date:March _23 rd 2022 | |
|----------------------------------------|-----------------------------------------------------------------------|
| Your Name:Hui Zhang | |
| Manuscript Title:_ Successful outcome | of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for |
| potentially unresectable esophagogastr | ic junctional squamous cell carcinoma: a case report |
| Manuscript number (if known): | TCR-22-789 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | the Basic Public Welfare Research Project of Zhejiang Province | Kai-Bo Chen was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) |
| | medical writing, article processing charges, etc.) No time limit for this item. | Natural Science foundation of Zhejiang Province (NO. LY19H160042) | Mu-Xing Kang was funded by Natural Science foundation of Zhejiang Province (NO. LY19H160042) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |

| 3 | Royalties or licenses | _ X None |
|----|----------------------------------------------------|-----------------|
| | | |
| 4 | Consulting fees | _ X None |
| | | |
| | | |
| 5 | Payment or honoraria for | _ X None |
| | lectures, presentations, speakers bureaus, | |
| | manuscript writing or educational events | |
| 6 | Payment for expert | X None |
| | testimony | |
| | | |
| 7 | Support for attending meetings and/or travel | _ X None |
| | | |
| | | |
| 8 | Patents planned, issued or | X None |
| | pending | |
| _ | | |
| 9 | Participation on a Data Safety Monitoring Board or | XNone |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | NNone |
| | committee or advocacy group, paid or unpaid | |
| 11 | Stock or stock options | _ X None |
| | | |
| | | |
| 12 | Receipt of equipment, | _ X None |
| | materials, drugs, medical | |
| | writing, gifts or other services | |
| 13 | Other financial or non- | _ X None |
| | financial interests | |
| | | |

This study was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) and Natural Science foundation of Zhejiang Province (No. LY19H160042). And there is no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date:March _23 rd 2022 | | |
|-------------------------------------------------------------------------------------------------------------|--|--|
| Your Name:Ya-Jing Huang | | |
| Manuscript Title:_ Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for | | |
| potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report | | |
| Manuscript number (if known): TCR-22-789 | | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | the Basic Public Welfare Research Project of Zhejiang Province | Kai-Bo Chen was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) |
| | medical writing, article processing charges, etc.) No time limit for this item. | Natural Science foundation of Zhejiang Province (NO. LY19H160042) | Mu-Xing Kang was funded by Natural Science foundation of Zhejiang Province (NO. LY19H160042) |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |

| 3 | Royalties or licenses | _ X None |
|----|---------------------------------------------------|-----------------|
| | | |
| 4 | Consulting fees | _ X None |
| | | |
| _ | | |
| 5 | Payment or honoraria for lectures, presentations, | _ X None |
| | speakers bureaus, | |
| | manuscript writing or educational events | |
| 6 | Payment for expert | XNone |
| | testimony | |
| | | |
| 7 | Support for attending meetings and/or travel | _ X None |
| | | |
| | | |
| 8 | Patents planned, issued or | _ X None |
| | pending | |
| | | |
| 9 | Participation on a Data | _ X None |
| | Safety Monitoring Board or Advisory Board | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | XNone |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | _ X None |
| | | |
| 12 | Descript of any in the | V |
| 12 | Receipt of equipment, materials, drugs, medical | _ X None |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | _ X None |
| | financial interests | |
| | | |

This study was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) and Natural Science foundation of Zhejiang Province (No. LY19H160042). And there is no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

| Date:March _23 rd 2022 |
|-------------------------------------------------------------------------------------------------------------|
| Your Name:Li Chen |
| Manuscript Title:_ Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for |
| potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report |
| Manuscript number (if known): TCR-22-789 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|--|--|
| | Time frame: Since the initial planning of the work | | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | the Basic Public Welfare Research Project of Zhejiang Province | Kai-Bo Chen was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) | | |
| | | Natural Science foundation of Zhejiang Province (NO. LY19H160042) | Mu-Xing Kang was funded by Natural Science foundation of Zhejiang Province (NO. LY19H160042) | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | Time frame: past 36 months | | | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _ X None | | | |

| 3 | Royalties or licenses | _ X None |
|----|--------------------------------------------------------------------------------------------------------------|-----------------|
| | | |
| 4 | Consulting fees | _ X None |
| | | |
| | | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _ X None |
| | | |
| | | |
| 6 | Payment for expert | V. Norre |
| 0 | testimony | XNone |
| | testimony | |
| 7 | Support for attending meetings and/or travel | _ X None |
| | | |
| | | |
| 8 | Patents planned, issued or | XNone |
| | pending | |
| _ | | |
| 9 | Participation on a Data Safety Monitoring Board or | X None |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | X None |
| 10 | in other board, society, | XNone |
| | committee or advocacy group, paid or unpaid | |
| 11 | Stock or stock options | X None |
| | ' | |
| | | |
| 12 | Receipt of equipment, | _ X None |
| | materials, drugs, medical | |
| | writing, gifts or other services | |
| 13 | Other financial or non- | _ X None |
| | financial interests | |
| | | |

This study was funded by the Basic Public Welfare Research Project of Zhejiang Province (No. LGF21H030005) and Natural Science foundation of Zhejiang Province (No. LY19H160042). And there is no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: